Mohan S. Iyer

Pendulum Therapeutics, Inc. engages in the development of therapeutics and diagnostics that target the human microbiome to improve the lives of patients suffering from various diseases. Its product pipeline includes WBF-011, WBF-020, WBF-012, and WBF-014.. The company was founded by Colleen Cutcliffe, John Eid, and James Bullard in 2012 and is headquartered in San Francisco, CA.

Sosv Ltd (Sosv) is a multi-stage venture capital and accelerator firm founded by Sean O’Sullivan in 1994. The firm is headquartered in Ireland with an additional offices in Luxembourg, USA, Hong Kong and China.

diaDexus is a privately held biotechnology company that is focused on the discovery, development and commercialization of novel, patent protected diagnostic products with high clinical value. diaDexus makes a difference by developing innovative products with clinical value to address significant unmet medical needs in the cardiovascular field.

Part of International Business Machines Corp., Wilkerson Group is a consulting company that provides services to the pharmaceutical and medical products industry. The company is based in New York, NY. The company was founded by Kenneth D. Noonan. The CEO is Neil MacAllister. Wilkerson Group was acquired by International Business Machines Corp. on April 01, 1996.

Second Genome, Inc. develops microbiome-based therapeutic products. It offers phyclochip community, 16S sequencing community analysis, whole metagenomic profiling, nucleic acid isolation, inferred function and custom informatics services. The company was founded in 2009 by Corey S. Goodman, Janet A. Warrington, Todd Z. DeSantis, John Hulls and Gary Andersen and is headquartered in South San Francisco, CA.

Tethys Bioscience was dedicated to the discovery, development and commercialization of novel biological markers biomarkers that provided a practical tool to address the growing global challenge of chronic metabolic diseases such as diabetes. By developing new tests that used protein and other blood borne biomarkers to identify people at high risk for devastating and preventable diseases, they can arm patients and physicians with knowledge they can use to help prevent disease progression. These biomarkers gave a snapshot of an individual's current risk, which may be modifiable. Their goal was to provide clinicians with an objective and convenient means to risk-stratify their patients and help them focus appropriate intervention strategies on those most likely to benefit. Their research strategies lead to sets of biomarkers that can be used to quantify the level of an individual's risk. The company had become a pioneer in the discovery, development and value creation of novel biological markers for the clinical diagnostics marketplace: The company had built expertise, created significant intellectual property, and was executing its business plan around three key areas: Biomarker Discovery, Clinical Validation and ValueCreation. It was focused upon introducing products that yield significant savings to the health care system and improve the quality of life for patients.

Burril LLC (Burrill) is a private equity/venture capital firm founded in 1994 by G. Steven. The firm is headquartered in San Francisco, California.